Multiplex high-throughput gene mutation analysis in acute myeloid leukemia

Jennifer Dunlap, Carol Beadling, Andrea Warrick, Tanaya Neff, William Fleming, Marc Loriaux, Michael Heinrich, Tibor Kovacsovics, Katalin Kelemen, Nicky Leeborg, Ken Gatter, Rita Braziel, Richard Press, Christopher Corless, Guang Fan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Classification of acute myeloid leukemia increasingly depends on genetic analysis. However, the number of known mutations in acute myeloid leukemia is expanding rapidly. Therefore, we tested a high-throughput screening method for acute myeloid leukemia mutation analysis using a multiplex mass spectrometry-based approach. To our knowledge, this is the first reported application of this approach to genotype leukemias in a clinical setting. One hundred seven acute myeloid leukemia cases were screened for mutations using a panel that covers 344 point mutations across 31 genes known to be associated with leukemia. The analysis was performed by multiplex polymerase chain reaction for mutations in genes of interest followed by primer extension reactions. Products were analyzed on a Sequenom MassARRAY system (San Diego, CA). The multiplex panel yielded mutations in 58% of acute myeloid leukemia cases with normal cytogenetics and 21% of cases with abnormal cytogenetics. Cytogenetics and routine polymerase chain reaction-based screening of NPM1, CEBPA, FLT3-ITD, and KIT was also performed on a subset of cases. When combined with the results of these standard polymerase chain reaction-based tests, the mutation frequency reached 78% in cases with normal cytogenetics. Of these, 42% harbored multiple mutations primarily involving NPM1 with NRAS, KRAS, CEBPA, PTPN11, IDH1, or FLT3. In contrast, cases with abnormal cytogenetics rarely harbored more than 1 mutation (1.5%), suggesting different underlying biology. This study demonstrates the feasibility and utility of broad-based mutation profiling of acute myeloid leukemia in a clinical setting. This approach will be helpful in defining prognostic subgroups of acute myeloid leukemia and contribute to the selection of patients for enrollment into trials with novel inhibitors.

Original languageEnglish (US)
Pages (from-to)2167-2176
Number of pages10
JournalHuman Pathology
Volume43
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Acute Myeloid Leukemia
Mutation
Cytogenetics
Genes
Leukemia
High-Throughput Screening Assays
Polymerase Chain Reaction
Multiplex Polymerase Chain Reaction
Feasibility Studies
Mutation Rate
Point Mutation
Patient Selection
Mass Spectrometry
Genotype

Keywords

  • Acute myeloid leukemia
  • Gene mutation
  • Genetics
  • Molecular

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. / Dunlap, Jennifer; Beadling, Carol; Warrick, Andrea; Neff, Tanaya; Fleming, William; Loriaux, Marc; Heinrich, Michael; Kovacsovics, Tibor; Kelemen, Katalin; Leeborg, Nicky; Gatter, Ken; Braziel, Rita; Press, Richard; Corless, Christopher; Fan, Guang.

In: Human Pathology, Vol. 43, No. 12, 12.2012, p. 2167-2176.

Research output: Contribution to journalArticle

@article{db28d5fc7742487381717e0180883e0d,
title = "Multiplex high-throughput gene mutation analysis in acute myeloid leukemia",
abstract = "Classification of acute myeloid leukemia increasingly depends on genetic analysis. However, the number of known mutations in acute myeloid leukemia is expanding rapidly. Therefore, we tested a high-throughput screening method for acute myeloid leukemia mutation analysis using a multiplex mass spectrometry-based approach. To our knowledge, this is the first reported application of this approach to genotype leukemias in a clinical setting. One hundred seven acute myeloid leukemia cases were screened for mutations using a panel that covers 344 point mutations across 31 genes known to be associated with leukemia. The analysis was performed by multiplex polymerase chain reaction for mutations in genes of interest followed by primer extension reactions. Products were analyzed on a Sequenom MassARRAY system (San Diego, CA). The multiplex panel yielded mutations in 58{\%} of acute myeloid leukemia cases with normal cytogenetics and 21{\%} of cases with abnormal cytogenetics. Cytogenetics and routine polymerase chain reaction-based screening of NPM1, CEBPA, FLT3-ITD, and KIT was also performed on a subset of cases. When combined with the results of these standard polymerase chain reaction-based tests, the mutation frequency reached 78{\%} in cases with normal cytogenetics. Of these, 42{\%} harbored multiple mutations primarily involving NPM1 with NRAS, KRAS, CEBPA, PTPN11, IDH1, or FLT3. In contrast, cases with abnormal cytogenetics rarely harbored more than 1 mutation (1.5{\%}), suggesting different underlying biology. This study demonstrates the feasibility and utility of broad-based mutation profiling of acute myeloid leukemia in a clinical setting. This approach will be helpful in defining prognostic subgroups of acute myeloid leukemia and contribute to the selection of patients for enrollment into trials with novel inhibitors.",
keywords = "Acute myeloid leukemia, Gene mutation, Genetics, Molecular",
author = "Jennifer Dunlap and Carol Beadling and Andrea Warrick and Tanaya Neff and William Fleming and Marc Loriaux and Michael Heinrich and Tibor Kovacsovics and Katalin Kelemen and Nicky Leeborg and Ken Gatter and Rita Braziel and Richard Press and Christopher Corless and Guang Fan",
year = "2012",
month = "12",
doi = "10.1016/j.humpath.2012.03.002",
language = "English (US)",
volume = "43",
pages = "2167--2176",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Multiplex high-throughput gene mutation analysis in acute myeloid leukemia

AU - Dunlap, Jennifer

AU - Beadling, Carol

AU - Warrick, Andrea

AU - Neff, Tanaya

AU - Fleming, William

AU - Loriaux, Marc

AU - Heinrich, Michael

AU - Kovacsovics, Tibor

AU - Kelemen, Katalin

AU - Leeborg, Nicky

AU - Gatter, Ken

AU - Braziel, Rita

AU - Press, Richard

AU - Corless, Christopher

AU - Fan, Guang

PY - 2012/12

Y1 - 2012/12

N2 - Classification of acute myeloid leukemia increasingly depends on genetic analysis. However, the number of known mutations in acute myeloid leukemia is expanding rapidly. Therefore, we tested a high-throughput screening method for acute myeloid leukemia mutation analysis using a multiplex mass spectrometry-based approach. To our knowledge, this is the first reported application of this approach to genotype leukemias in a clinical setting. One hundred seven acute myeloid leukemia cases were screened for mutations using a panel that covers 344 point mutations across 31 genes known to be associated with leukemia. The analysis was performed by multiplex polymerase chain reaction for mutations in genes of interest followed by primer extension reactions. Products were analyzed on a Sequenom MassARRAY system (San Diego, CA). The multiplex panel yielded mutations in 58% of acute myeloid leukemia cases with normal cytogenetics and 21% of cases with abnormal cytogenetics. Cytogenetics and routine polymerase chain reaction-based screening of NPM1, CEBPA, FLT3-ITD, and KIT was also performed on a subset of cases. When combined with the results of these standard polymerase chain reaction-based tests, the mutation frequency reached 78% in cases with normal cytogenetics. Of these, 42% harbored multiple mutations primarily involving NPM1 with NRAS, KRAS, CEBPA, PTPN11, IDH1, or FLT3. In contrast, cases with abnormal cytogenetics rarely harbored more than 1 mutation (1.5%), suggesting different underlying biology. This study demonstrates the feasibility and utility of broad-based mutation profiling of acute myeloid leukemia in a clinical setting. This approach will be helpful in defining prognostic subgroups of acute myeloid leukemia and contribute to the selection of patients for enrollment into trials with novel inhibitors.

AB - Classification of acute myeloid leukemia increasingly depends on genetic analysis. However, the number of known mutations in acute myeloid leukemia is expanding rapidly. Therefore, we tested a high-throughput screening method for acute myeloid leukemia mutation analysis using a multiplex mass spectrometry-based approach. To our knowledge, this is the first reported application of this approach to genotype leukemias in a clinical setting. One hundred seven acute myeloid leukemia cases were screened for mutations using a panel that covers 344 point mutations across 31 genes known to be associated with leukemia. The analysis was performed by multiplex polymerase chain reaction for mutations in genes of interest followed by primer extension reactions. Products were analyzed on a Sequenom MassARRAY system (San Diego, CA). The multiplex panel yielded mutations in 58% of acute myeloid leukemia cases with normal cytogenetics and 21% of cases with abnormal cytogenetics. Cytogenetics and routine polymerase chain reaction-based screening of NPM1, CEBPA, FLT3-ITD, and KIT was also performed on a subset of cases. When combined with the results of these standard polymerase chain reaction-based tests, the mutation frequency reached 78% in cases with normal cytogenetics. Of these, 42% harbored multiple mutations primarily involving NPM1 with NRAS, KRAS, CEBPA, PTPN11, IDH1, or FLT3. In contrast, cases with abnormal cytogenetics rarely harbored more than 1 mutation (1.5%), suggesting different underlying biology. This study demonstrates the feasibility and utility of broad-based mutation profiling of acute myeloid leukemia in a clinical setting. This approach will be helpful in defining prognostic subgroups of acute myeloid leukemia and contribute to the selection of patients for enrollment into trials with novel inhibitors.

KW - Acute myeloid leukemia

KW - Gene mutation

KW - Genetics

KW - Molecular

UR - http://www.scopus.com/inward/record.url?scp=84869497111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869497111&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2012.03.002

DO - 10.1016/j.humpath.2012.03.002

M3 - Article

VL - 43

SP - 2167

EP - 2176

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 12

ER -